Cystic fibrosis (CF) is a life‑limiting genetic disorder caused by mutations in the CFTR gene, which disrupts chloride and bicarbonate transport across epithelial surfaces. This defect leads to thick, sticky secretions that progressively damage the lungs, pancreas, liver, intestines, and reproductive organs. Over time, pancreatic damage impairs both exocrine function (digestive enzyme production) and endocrine function (insulin secretion). Cystic fibrosis‑related diabetes (CFRD) is the most common comorbidity in people with CF, affecting approximately 20% of adolescents and up to 50% of adults over age 30. CFRD is distinct from type 1 and type 2 diabetes: it primarily results from insulin deficiency due to beta‑cell destruction from pancreatic fibrosis and fatty infiltration, combined with intermittent insulin resistance during acute illness, infection, or corticosteroid use. Unlike typical diabetes, CFRD often develops insidiously, and hyperglycemia can go unrecognized for months or years, leading to worsening lung function, nutritional decline, and increased mortality.

Annual screening with an oral glucose tolerance test (OGTT) is recommended starting at age 10 because early detection and treatment of CFRD can prevent further decline in lung function, improve body mass index (BMI), and reduce mortality. The OGTT is the gold standard for diagnosis, as hemoglobin A1c is less reliable in CF due to altered red blood cell turnover caused by chronic inflammation and nutritional deficiencies. Continuous glucose monitoring (CGM) is increasingly used to detect glycemic abnormalities earlier than OGTT alone.

Why Insulin Therapy Is the Cornerstone of CFRD Management

Because CFRD is primarily a disease of insulin insufficiency, exogenous insulin replacement is the only therapy proven to safely and effectively control blood glucose in this population. Oral hypoglycemic agents such as metformin or sulfonylureas are not recommended as first‑line therapy for CFRD. Metformin carries a risk of lactic acidosis in patients with compromised liver or kidney function, and sulfonylureas can cause prolonged hypoglycemia in individuals with erratic food intake and variable absorption due to pancreatic insufficiency. In contrast, insulin therapy can be precisely titrated to match the patient’s unique pattern of insulin needs, which fluctuate with nutritional status, acute infections, and corticosteroid use.

The goals of insulin therapy in CFRD are to maintain blood glucose levels as close to normal as possible while minimizing hypoglycemia, to support optimal nutritional intake (including high‑calorie diets), and to prevent diabetic complications such as microvascular disease, worsening lung function, and malnutrition. Large cohort studies have shown that insulin treatment in CFRD is associated with stabilization or improvement of BMI and forced expiratory volume in one second (FEV₁). Early intervention with insulin can also reduce the frequency of pulmonary exacerbations and improve overall survival. A landmark 2018 study published in Diabetes Care demonstrated that every 1% increase in hemoglobin A1c was associated with a 1.5‑fold increase in pulmonary exacerbation risk, underscoring the critical role of glycemic control.

Types of Insulin Used in CFRD

Insulin regimens for CFRD are tailored to the patient’s lifestyle, meal pattern, and glucose monitoring data. The most common approach uses a basal‑bolus regimen that mimics physiological insulin secretion. Healthcare providers typically start with conservative doses and adjust based on frequent glucose monitoring, especially during periods of illness or weight change.

Rapid‑acting insulin

Rapid‑acting insulin analogues such as insulin lispro (Humalog), aspart (NovoLog), and glulisine (Apidra) are administered immediately before or after meals to control postprandial hyperglycemia. Their onset of action is within 10–15 minutes, peak at about 1–2 hours, and duration of 3–4 hours. Because CFRD patients often eat high‑carbohydrate, high‑calorie snacks, accurate mealtime dosing is critical. Many patients learn to dose based on carbohydrate counting using an insulin‑to‑carbohydrate ratio, with adjustments for pre‑meal glucose levels and planned activity. Recent studies suggest that dosing insulin shortly after the meal (postprandial dosing) can be safe and effective for patients with unpredictable appetites, a common feature in CF.

Intermediate‑ and long‑acting insulin

Basal insulin provides background coverage between meals and overnight. Neutral protamine Hagedorn (NPH) insulin is an intermediate‑acting option that peaks around 4–8 hours and lasts 12–16 hours. However, its peak action increases the risk of nocturnal hypoglycemia, so it is used less often in modern practice. Long‑acting insulin analogues such as insulin glargine (Lantus, Basaglar, Toujeo) and insulin degludec (Tresiba) provide a relatively peakless, steady insulin level over 24 hours with a single daily injection. Insulin detemir (Levemir) is another long‑acting option, though its duration may be dose‑dependent and often requires twice‑daily dosing. The newer ultra‑long‑acting insulin degludec has a duration beyond 42 hours and shows lower day‑to‑day variability, which may be advantageous for patients with unpredictable schedules. Clinical trials have demonstrated that degludec reduces the risk of nocturnal hypoglycemia compared to glargine in adults with CFRD.

Insulin pump therapy

Continuous subcutaneous insulin infusion (CSII) via an insulin pump is an alternative for patients who require flexible dosing or have persistent nocturnal hypoglycemia. Pumps deliver a continuous basal rate of rapid‑acting insulin, and the user gives additional boluses at meals and for corrections. In CF, pumps can be especially useful during periods of high caloric intake or when gastrointestinal complications impair absorption. Some centers use hybrid closed‑loop systems (insulin pumps integrated with continuous glucose monitors) in select patients, though evidence in CFRD is still emerging. A 2021 pilot study showed that hybrid closed‑loop therapy improved time‑in‑range by 12% without increasing hypoglycemia in adults with CFRD.

Administration and Monitoring

Insulin is injected subcutaneously using a syringe, pen device, or insulin pump. Proper injection technique—rotating sites in the abdomen, thighs, or arms—is essential to prevent lipohypertrophy (fatty lumps that can impair absorption). Patients are taught to use a new needle each time and to avoid injecting into areas prone to infection or scarring. For those using insulin pens, careful attention to priming and needle disposal is important.

Frequent blood glucose monitoring is the cornerstone of safe insulin therapy. The Cystic Fibrosis Foundation guidelines recommend self‑monitoring at least four times daily: before meals, 2 hours after the largest meal, and at bedtime. For patients using insulin pumps or those with unpredictable glucose patterns, continuous glucose monitoring (CGM) systems such as the Dexcom G6 or Abbott FreeStyle Libre can provide real‑time trends and alarms for hypoglycemia. Evidence suggests that CGM improves glycemic control and reduces fear of low blood glucose in both children and adults with CFRD. Glucose targets in CFRD are slightly different from other diabetes types: pre‑meal glucose should be 90–130 mg/dL, and 2‑hour post‑prandial glucose less than 180 mg/dL. Hemoglobin A1c is less reliable in CF because of altered red blood cell turnover, so the diagnosis and monitoring of glycemic control rely more on CGM metrics and OGTT results.

During acute pulmonary exacerbations, insulin requirements can double or triple. Inpatient management often requires insulin infusions or frequent subcutaneous doses, with close monitoring of blood glucose every 1–2 hours. After resolution of the exacerbation, insulin doses typically return to baseline, but providers should reassess the patient’s home regimen before discharge.

Benefits of Insulin Therapy in CFRD

When implemented properly, insulin therapy transforms the trajectory of CFRD. Multiple observational studies have demonstrated that patients with CFRD who receive insulin have a significant attenuation of the decline in FEV₁ compared to those left untreated. Insulin improves anabolic metabolism, allowing patients to gain weight even when lung function is stable. By correcting insulinopenia, insulin facilitates the storage of nutrients—especially glucose into muscle and fat—and reduces the catabolic wasting that is common in CF. The nutritional benefits are especially pronounced in underweight patients, where weight gain of 2–3 kg within six months is not uncommon.

Better glycemic control also lowers the risk of acute diabetic complications such as diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS), though these are less common in CFRD than in type 1 diabetes. Long‑term microvascular complications (retinopathy, nephropathy, neuropathy) occur in CFRD patients with poor control, and insulin therapy can help prevent or delay these. A 2020 registry study found that patients with CFRD who maintained hemoglobin A1c below 7% had a 40% lower risk of microvascular complications compared to those with A1c above 8%.

Insulin therapy also plays a role in managing pulmonary exacerbations. During acute illness or when high‑dose corticosteroids are given, insulin requirements often double or triple. Proactive insulin adjustment during hospitalizations has been shown to reduce length of stay and improve recovery of lung function. Moreover, treating CFRD with insulin is associated with lower rates of chronic Pseudomonas aeruginosa infection and a reduced frequency of exacerbations. The mechanism may involve improved immune function and reduced hyperglycemia‑induced oxidative stress in the airways.

Challenges and Considerations

While insulin is highly effective, its use in CFRD presents unique challenges. The first is the risk of hypoglycemia, which can be exacerbated by caloric goals that demand constant eating, variable absorption of nutrients due to pancreatic insufficiency, and increased physical activity. Patients need clear sick‑day rules and careful education on “hypo” recognition and treatment (e.g., 15 g of fast‑acting carbohydrates). Insulin doses must be adjusted before, during, and after exercise, and during febrile illnesses (insulin resistance rises). For patients with frequent hypoglycemia, a temporary reduction in basal insulin or use of a CGM with predictive alarms can be helpful.

Another challenge is the psychological burden of intensive insulin therapy. Many CF patients already manage a heavy treatment regimen (airway clearance, inhaled medications, pancreatic enzymes, vitamins). Adding multiple daily injections and frequent glucose monitoring can contribute to treatment fatigue. Behavioral interventions, diabetes education integrated into CF care teams, and peer support can improve adherence. Screening for diabetes distress and depression should be part of routine care.

Dosing during periods of enteral tube feeding or parenteral nutrition requires specialized guidance. For patients on nocturnal tube feedings, a bolus of rapid‑acting insulin at the start of the feed or a temporary basal rate increase on a pump may be needed. Close collaboration between the CF dietitian, endocrinologist, and nursing staff is essential. Patients on total parenteral nutrition often require insulin added to the bag or separate intravenous insulin infusions with frequent glucose monitoring.

Finally, the cost of insulin and supplies can be a barrier. Healthcare providers should discuss assistance programs, insurance coverage, and generic options (e.g., insulin lispro is now available in lower‑cost versions). Advocacy for affordable insulin remains a public health priority. The American Diabetes Association offers a resource guide for insulin access and affordability.

Emerging Treatments and Research

Insulin remains the cornerstone, but several areas of research aim to improve outcomes. Inhaled insulin (Afrezza) has been studied in CFRD with mixed results; its rapid absorption mimics first‑pass hepatic insulin delivery, but the requirement for a pulmonary function test and the risk of bronchospasm in patients with underlying lung disease have limited its adoption. A 2022 phase 2 trial suggested that inhaled insulin may be a viable option for selected patients with mild lung disease, but further studies are needed.

Non‑insulin injectables like glucagon‑like peptide‑1 (GLP‑1) receptor agonists (e.g., liraglutide) are being investigated for their potential to reduce postprandial glucose without causing hypoglycemia, but safety data in CF are scarce, and concerns about gastrointestinal side effects remain. A small randomized trial of liraglutide in CFRD is ongoing.

The use of CFTR modulator therapies—ivacaftor, lumacaftor, tezacaftor, and elexacaftor—has been a game‑changer for many people with CF. Emerging evidence suggests that these modulators may improve pancreatic endocrine function, as measured by increased insulin secretion and improved glucose tolerance in some patients. A 2023 cohort study found that patients treated with elexacaftor/tezacaftor/ivacaftor experienced a significant improvement in glucose tolerance and a reduction in insulin requirements. However, the effect is not uniform; many patients with advanced pancreatic damage still develop CFRD. Nonetheless, for those with residual beta‑cell function, modulators may delay the onset of diabetes or reduce insulin requirements.

Clinical trials are also exploring closed‑loop insulin delivery systems (artificial pancreas) for CFRD. These systems automate insulin delivery based on CGM data, potentially reducing the burden of self‑management. Preliminary studies have shown improved time‑in‑range without increasing hypoglycemia, and larger randomized trials are ongoing. The CamAPS FX closed‑loop system is being tested in a multicenter trial for adolescents and adults with CFRD.

Conclusion

For cystic fibrosis patients developing diabetic complications, insulin therapy is not just an option—it is an essential, evidence‑based treatment that directly impacts survival, lung function, and nutritional status. Understanding the unique pathophysiology of CFRD, selecting the appropriate insulin types and regimens, and providing intensive self‑management education are key to successful outcomes. The integration of continuous glucose monitoring, close multidisciplinary follow‑up, and the potential of CFTR modulators offer hope for even better glucose control with fewer burdens. As research continues to refine insulin protocols and explore adjunctive therapies, the immediate message is clear: early recognition and insulin treatment of CFRD can dramatically improve the quality and length of life for people with cystic fibrosis.

External resources: Readers can explore the Cystic Fibrosis Foundation’s guidelines on CFRD, the 2020 American Diabetes Association consensus report on CFRD, and evidence summaries on insulin use in CF from PubMed for a deeper dive into dosing strategies. The CDC’s page on diabetes in cystic fibrosis offers additional patient‑friendly information.